NMPA China Medical Device Registration & Approval

Medical devices and in vitro diagnostics in China are regulated by the National Medical Products Administration (NMPA). NMPA handles imported Class I filings and imported Class II/III registrations; domestic Class II registration has a different provincial authority allocation. Current regulations, notices, and guidance are available through the NMPA medical devices portal.

China medical device classification

China uses three risk classes. Class I covers lower-risk products and generally follows a filing route. Class II and Class III products generally require registration, with the evidence and review depth increasing with risk. Classification should be confirmed against the Chinese classification catalogue and rules; a US or EU class is useful background but does not determine the Chinese result.

Software, AI-enabled devices, combination products, innovative technologies, and IVDs may trigger product-specific classification and evidence questions. A careful intended-use statement and product boundary analysis should be completed before testing or dossier preparation because they drive standards, clinical evaluation, and labeling.

Domestic agent and registration evidence

An overseas applicant appoints a China-based agent to manage regulatory communications and specified lifecycle responsibilities. The agreement should address dossier access, supplemental questions, change reporting, renewal, complaints, adverse events, recalls, and transfer planning.

A registration file typically includes administrative and manufacturer information, product technical requirements, risk management, research and verification reports, applicable standards, inspection or testing evidence, clinical evaluation, labeling and instructions for use in Chinese, and quality-system information. Whether local testing, exemption pathways, or overseas reports can be used depends on the device and current NMPA rules. Class I filing still requires a technically complete package even though it is not reviewed like a Class II or III registration.

Review, labeling, and lifecycle

NMPA may issue supplemental-information requests during technical review. Project plans should reserve time for testing, translation, legalized documents where applicable, and consistent responses across the dossier. Approved product names, models, specifications, manufacturing sites, intended use, and labels must stay aligned.

After market entry, the manufacturer and agent need procedures for complaints, adverse-event monitoring, corrective actions, recalls, and regulatory reporting. Changes should be assessed before implementation to determine whether they require a change registration, notification, new filing, or documentation in the quality system. Registration renewal work should begin early enough to preserve continuity of supply.

China pathway and evidence decisions

Chinese classification, product technical requirements and evidence must align. An exemption from clinical evaluation or a route using existing clinical data must be assessed under its actual conditions; the absence of a local trial is not automatically a deficiency. Separate product testing, clinical evaluation and quality-system work.

Use the official NMPA instructions for the filing scope. Maintain a controlled record of the chosen route, current evidence, open gaps, responsible parties and authority responses. Separate fees, document preparation, review and applicant work when planning the launch.

For a multi-country program, use the market directory to coordinate evidence reuse while retaining the local applicant, language, registration and postmarket requirements for each destination.